Evidence map›Paper›PMID 42124796›Full record

ArticleMolecular imaging

Bone Tracers for Transthyretin Amyloid Cardiomyopathy: Are [

Julien Dubois, Florentin Kucharczak, Denis Mariano-Goulart, Tom Paunet

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular imaging. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Julien DuboisRadiopharmacy Department, Montpellier University Hospital, Montpellier, France.ORCID https://orcid.org/0009-0007-1046-3200
Florentin KucharczakNuclear Medicine department, Montpellier University Hospital, Montpellier, France.ORCID https://orcid.org/0000-0002-9750-6766
Denis Mariano-GoulartNuclear Medicine department, Montpellier University Hospital, Montpellier, France.
Tom PaunetNuclear Medicine department, Montpellier University Hospital, Montpellier, France.ORCID https://orcid.org/0000-0001-7665-1895

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The management of transthyretin amyloid cardiomyopathy (ATTR-CM) has revolved around the scintigraphic diagnosis since the introduction of a specific treatment; however, the equivalency of the bone radiotracers remains unclear. This retrospective monocentric observational study compared [

Indexed as

Amyloid Neuropathies, FamilialBone and BonesCardiomyopathiesDiphosphonatesOrganotechnetium CompoundsTechnetium Tc 99m ExametazimeTechnetium Tc 99m MedronateAgedAged, 80 and overFemaleHumansMaleRadionuclide ImagingRadiopharmaceuticalsRetrospective StudiesDiphosphonatesOrganotechnetium CompoundsRadiopharmaceuticalstechnetium Tc 99m 1,1-diphosphonopropane-2,3-dicarboxylic acidTechnetium Tc 99m Exametazimetechnetium Tc 99m hydroxymethylene diphosphonateTechnetium Tc 99m Medronate[99mTc]Tc-DPD[99mTc]Tc-HMDPATTR-CMcardiac amyloidosisheart to mediastinum ratio

Identifiers

PMID42124796
PMCPMC13158494

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.